Eli Lilly and Receives Average Recommendation of “Buy” from Analysts (NYSE:LLY)
Eli Lilly and (NYSE:LLY) has received an average recommendation of “Buy” from the twenty-two analysts that are currently covering the stock, ARN reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $64.33.
Eli Lilly and (NYSE:LLY) opened at 63.00 on Thursday. Eli Lilly and has a 52-week low of $47.53 and a 52-week high of $65.70. The stock’s 50-day moving average is $62.25 and its 200-day moving average is $59.96. The company has a market cap of $67.517 billion and a price-to-earnings ratio of 20.01.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Thursday, July 24th. The company reported $0.68 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.65 by $0.03. The company had revenue of $4.94 billion for the quarter, compared to the consensus estimate of $4.88 billion. During the same quarter last year, the company posted $1.16 earnings per share. Eli Lilly and’s revenue was down 16.8% compared to the same quarter last year. On average, analysts predict that Eli Lilly and will post $2.78 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Deutsche Bank initiated coverage on shares of Eli Lilly and in a research note on Wednesday. They set a “buy” rating and a $71.00 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Eli Lilly and from $65.00 to $61.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Finally, analysts at S&P Equity Research initiated coverage on shares of Eli Lilly and in a research note on Friday, August 1st. They set a “buy” rating on the stock.
Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.